Assignee
ALEXION PHARMA INC
US162 patents
Top patents by PatentIndex Score
US9079949B1Jul 14, 2015
Anti-C5 antibodies having improved pharmacokinetics
ALEXION PHARMA INC182 citations99
US9663574B2May 30, 2017
Anti-C5 antibodies having improved pharmacokinetics
ALEXION PHARMA INC24 citations98
US9206251B2Dec 8, 2015
Nucleic acids encoding anti-C5 antibodies having improved pharmacokinetics
ALEXION PHARMA INC36 citations98
US9107861B1Aug 18, 2015
Methods of treating C5 mediated complement-associated conditions with anti-C5 antibodies having improved pharmacokinetics
ALEXION PHARMA INC58 citations98
US6355245B1Mar 12, 2002
C5-specific antibodies for the treatment of inflammatory diseases
ALEXION PHARMA INC465 citations97
US7435412B2Oct 14, 2008
Chronic lymphocytic leukemia cell line
ALEXION PHARMA INC34 citations96
US7408041B2Aug 5, 2008
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
ALEXION PHARMA INC39 citations96
US7306906B2Dec 11, 2007
Engineered templates and their use in single primer amplification
ALEXION PHARMA INC123 citations96
US6982323B1Jan 3, 2006
Chimeric proteins for diagnosis and treatment of diabetes
ALEXION PHARMA INC70 citations96
US6074642AJun 13, 2000
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
ALEXION PHARMA INC117 citations96
US5853722ADec 29, 1998
Use of C5-specific antibodies for reducing immune and hemostatic dysfunctions during extracorporeal circulation
ALEXION PHARMA INC73 citations96
US7396917B2Jul 8, 2008
Rationally designed antibodies
ALEXION PHARMA INC46 citations95
US7393648B2Jul 1, 2008
Hybrid antibodies
ALEXION PHARMA INC86 citations95
US5847082ADec 8, 1998
Terminal complement inhibitor fusion proteins
ALEXION PHARMA INC60 citations95
US11434280B2Sep 6, 2022
Anti-C5 antibodies having improved pharmacokinetics
ALEXION PHARMA INC10 citations94
US10584164B2Mar 10, 2020
Methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with anti-C5 antibodies
ALEXION PHARMA INC11 citations94
US10227400B2Mar 12, 2019
Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodies
ALEXION PHARMA INC14 citations94
US6338820B1Jan 15, 2002
Apparatus for performing assays at reaction sites
ALEXION PHARMA INC96 citations94
US5627264AMay 6, 1997
Chimeric complement inhibitor proteins
ALEXION PHARMA INC54 citations94
US5624837AApr 29, 1997
Nucleic acid encoding chimeric complement inhibitor proteins
ALEXION PHARMA INC62 citations94
US9803007B1Oct 31, 2017
Anti-C5 antibodies having improved pharmacokinetics
ALEXION PHARMA INC14 citations92
US9732149B2Aug 15, 2017
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
ALEXION PHARMA INC15 citations92
US9725504B2Aug 8, 2017
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
ALEXION PHARMA INC14 citations92
US9718880B2Aug 1, 2017
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
ALEXION PHARMA INC17 citations92
US9371377B2Jun 21, 2016
Anti-C5 antibodies having improved pharmacokinetics
ALEXION PHARMA INC22 citations92
US9221901B2Dec 29, 2015
Methods of treating complement-associated disorders with anti-C5a antibodies
ALEXION PHARMA INC11 citations92
US7427665B2Sep 23, 2008
Chronic lymphocytic leukemia cell line
ALEXION PHARMA INC20 citations92
US7361339B2Apr 22, 2008
Methods for reducing morality associated with acute myocardial infarction
ALEXION PHARMA INC25 citations92
US5643770AJul 1, 1997
Retroviral vector particles expressing complement inhibitor activity
ALEXION PHARMA INC39 citations92
US9409980B1Aug 9, 2016
Methods for treating patients with complement-associated disorders with high concentration formulations of anti-C5 antibodies
ALEXION PHARMA INC11 citations91
US9352035B2May 31, 2016
High concentration antibody formulations
ALEXION PHARMA INC20 citations91
US7482435B2Jan 27, 2009
Rationally designed antibodies
ALEXION PHARMA INC20 citations91
US5871997AFeb 16, 1999
Methods and compositions for protecting retroviral vector particles and producer cells from inactivation by complement via reduction of the expression or recognition of galactose alpha (1,3) galactosyl epitopes
ALEXION PHARMA INC19 citations90
US9494601B2Nov 15, 2016
Atypical hemolytic uremic syndrome (AHUS) biomarker proteins
ALEXION PHARMA INC14 citations89
US7279158B2Oct 9, 2007
Methods for the treatment of inflammatory joint disease
ALEXION PHARMA INC18 citations89
US5576201ANov 19, 1996
Retroviral vector particles for transducing non-proliferating cells
ALEXION PHARMA INC26 citations89
US10449236B2Oct 22, 2019
Treating seizure with recombinant alkaline phosphatase
ALEXION PHARMA INC17 citations87
US10954503B2Mar 23, 2021
Antidotes for factor Xa inhibitors and methods of using the same
ALEXION PHARMA INC4 citations84
US10703809B1Jul 7, 2020
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
ALEXION PHARMA INC3 citations84
US10603361B2Mar 31, 2020
Methods of treating a subject with an alkaline phosphatase deficiency
ALEXION PHARMA INC16 citations84
US10590189B2Mar 17, 2020
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
ALEXION PHARMA INC7 citations84
US9469690B2Oct 18, 2016
Methods of treating complement-associated disorders with anti-C5a antibodies
ALEXION PHARMA INC4 citations84
US9434784B1Sep 6, 2016
Nucleic acids encodng anti-C5A antibodies
ALEXION PHARMA INC4 citations84
US9371378B1Jun 21, 2016
Anti-C5a antibodies
ALEXION PHARMA INC7 citations84
US9309310B2Apr 12, 2016
Nucleic acids encoding anti-C5a antibodies
ALEXION PHARMA INC7 citations84
US7714110B2May 11, 2010
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
ALEXION PHARMA INC8 citations84
US7598353B2Oct 6, 2009
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
ALEXION PHARMA INC10 citations84
US9771418B2Sep 26, 2017
Methods for treating complement-associated disorders
ALEXION PHARMA INC8 citations83
US9556263B2Jan 31, 2017
Methods for treating atypical hemolytic uremic syndrome with high concentration formulations of anti-C5 antibodies
ALEXION PHARMA INC7 citations83
US9000133B2Apr 7, 2015
Antibodies to OX-2/CD200 and uses thereof
ALEXION PHARMA INC6 citations83
Showing the top 50 of 162 patents by PatentIndex Score.